No Data
SymbolStock Name
PriceChg% ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D % Chg10D % Chg20D % Chg60D % Chg120D % Chg250D % Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
Watchlist
US OptionsDetailed Quotes
REPL250117P15000
- 2.10
- 0.000.00%
15min DelayClose Jan 10 15:59 ET
0.00High0.00Low
2.10Open2.10Pre Close0 Volume2 Open Interest15.00Strike Price0.00Turnover151.13%IV-16.64%PremiumJan 17, 2025Expiry Date3.94Intrinsic Value100Multiplier6DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type-0.9254Delta0.0658Gamma2.77Leverage Ratio-0.0218Theta-0.0018Rho-2.56Eff Leverage0.0020Vega
Intraday
- 5D
- Daily
News
Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Express News | Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Replimune Begins RP2 Clinical Trials With First Patients Enrolled In Metastatic Uveal Melanoma And Hepatocellular Carcinoma
Express News | Replimune Group Inc - Primary Endpoints of Rp2-202 Study Are Overall Survival and Progression Free Survival
Replimune to Present at the 43rd Annual J.P. Morgan Healthcare Conference
Analysts Are Bullish on These Healthcare Stocks: Inovio Pharmaceuticals (INO), Replimune Group (REPL)